Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806742 | 0.72 | TSHR (0.37) | TSHR | |
| SCHEMBL8741525 | 0.67 | — | — | |
| SCHEMBL1059438 | 0.67 | — | — | |
| SCHEMBL610211 | 0.64 | TSHR (0.47) | TSHR | |
| SCHEMBL1146068 | 0.64 | — | — | |
| SCHEMBL1117784 | 0.64 | — | — | |
| SCHEMBL10716728 | 0.64 | — | — | |
| SCHEMBL1064223 | 0.62 | TSHR (0.33) | TSHR | |
| SCHEMBL8059804 | 0.62 | TSHR (0.32) | TSHR | |
| SCHEMBL1500729 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221347-A1 | Sulfonated diarylrhodamine dyes | Applera Corporation (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-2179996-A1 | Sulfonated diarylrhodamine dyes | Applera Corporation (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20070254298-A1 | ATROPISOMERS OF ASYMMETRIC XANTHENE FLUORESCENT DYES AND METHOD OF DNA SEQUENCING AND FRAGMENT ANALYSIS | APPLERA CORPORATION, APPLIED BIOSYSTEMS GROUP (US) | 2007-11-01 | — | — | US | disclosed |
| US-20060188915-A1 | ATROPISOMERS OF ASYMMETRIC XANTHENE FLUORESCENT DYES AND METHODS OF DNA SEQUENCING AND FRAGMENT ANALYSIS | APPLERA CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-7038063-B2 | Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis | APPLERA CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-7018431-B2 | Sulfonated diarylrhodamine dyes | APPLERA CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040229235-A1 | Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis | APPLERA CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040096397-A1 | Sulfonated diarylrhodamine dyes | APPLERA CORPORATION (US) | 2004-05-20 | — | — | US | disclosed |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | disclosed |
| US-6448407-B1 | LABELS FOR SUCH AS NUCLEOTIDES, NUCLEOSIDES, POLYPEPTIDES, POLYNUCLEOTIDES AND CARBOHYDRATES; SEQUENCING, FRAGMENT ANALYSIS, OLIGONUCLEOTIDE LIGATION, AMPLIFICATION, MINISEQUENCING, AND PRIMER EXTENSION | PE CORPORATION (NY) | 2002-09-10 | — | — | US | disclosed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2002044416-A2 | SULFONATED DIARYLRHODAMINE DYES AS FLUORESCENT LABELS | APPLERA CORPORATION (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002036832-A2 | ATROPISOMERS OF ASYMMETRIC XANTHENE FLUORESCENT DYES AND METHODS OF DNA SEQUENCING AND FRAGMENT ANALYSIS | APPLERA CORPORATION (US) | 2002-05-10 | — | — | WO | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| EP-0424819-A1 | Reversible modification of biological compounds for detection, separation and purification thereof | MILLIPORE CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040096397-A1 | Sulfonated diarylrhodamine dyes | POLL, DUT, DPYD | TSHR 3761/4885 |
| US-20060188915-A1 | ATROPISOMERS OF ASYMMETRIC XANTHENE FLUORESCENT DYES AND METHODS OF DNA SEQUENCING AND FRAGMENT ANALYSIS | CHRNB3, CHRNB4, SPR | TSHR 2831/4885 |
| US-20070254298-A1 | ATROPISOMERS OF ASYMMETRIC XANTHENE FLUORESCENT DYES AND METHOD OF DNA SEQUENCING AND FRAGMENT ANALYSIS | CHRNB3, CHRNB4, SPR | TSHR 2773/4885 |
| US-20040229235-A1 | Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis | CHRNB3, CHRNB4, SPR | TSHR 2831/4885 |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | NSUN2, RNMT, HNRNPL | TSHR 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.